Theravance Biopharma
TBPH
TBPH
108 hedge funds and large institutions have $1.16B invested in Theravance Biopharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
17% more funds holding
Funds holding: 92 → 108 (+16)
2.59% less ownership
Funds ownership: 81.55% → 78.97% (-2.6%)
45% less call options, than puts
Call options by funds: $726K | Put options by funds: $1.33M
Holders
108
Holding in Top 10
3
Calls
$726K
Puts
$1.33M
Top Buyers
| 1 | +$82.3M | |
| 2 | +$9.1M | |
| 3 | +$4.49M | |
| 4 |
Norges Bank
Oslo,
Norway
|
+$3.11M |
| 5 |
NM
Newtyn Management
New York
|
+$2.84M |
Top Sellers
| 1 | -$5.09M | |
| 2 | -$2.52M | |
| 3 | -$1.79M | |
| 4 |
Squarepoint
New York
|
-$967K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$722K |